This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.
Syndax (SNDX) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Syndax (SNDX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of Opzelura.
Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $20.10, marking a -0.94% move from the previous day.
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed at $20.91 in the latest trading session, marking a -0.99% move from the prior day.
Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $21.94, moving +1.72% from the previous trading session.
Syndax Pharmaceuticals (SNDX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $23.07, marking a -0.26% move from the previous day.
Syndax Pharmaceuticals (SNDX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $22.30, moving -1.24% from the previous trading session.
Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed the most recent trading day at $22.58, moving +0.71% from the previous trading session.
Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Syndax Pharmaceuticals (SNDX) Stock Moves -1.99%: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed at $25.64 in the latest trading session, marking a -1.99% move from the prior day.
Anika (ANIK) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Anika Therapeutics' (ANIK) Q4 earnings call, investors are likely to focus on the sales performance of its Osteoarthritis Pain (OAP) Management, Joint Preservation and Restoration segments.
Syndax (SNDX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors' focus will be on Syndax Pharmaceuticals' (SNDX) pipeline progress when it reports its fourth-quarter earnings.
Syndax Pharmaceuticals (SNDX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Syndax Pharmaceuticals (SNDX) closed at $25.77, marking a +1.38% move from the previous day.
Acer (ACER) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Acer Therapeutics' (ACER) fourth-quarter earnings call, investors' focus is likely to be on the company's pipeline development.
Novavax (NVAX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) fourth-quarter earnings call, investors' focus is likely to be on the sales figures of its COVID-19 vaccine.
Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants
by Zacks Equity Research
Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Devoid of marketed drugs, investors' focus will be on CRISPR Therapeutics' (CRSP) pipeline, specifically its lead candidate exa-cel, in its fourth-quarter earnings.
Exelixis (EXEL) Q4 Earnings Top, Revenues Beat on Cabometyx
by Zacks Equity Research
Exelixis (EXEL) beats earnings and sales estimates for the fourth quarter due to increased Cabometyx sales volume.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Syndax Pharmaceuticals (SNDX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) closed at $26.57 in the latest trading session, marking a +0.15% move from the prior day.
Incyte's (INCY) Q4 Earnings, Revenues Top on Jakafi, Opzelura
by Zacks Equity Research
Incyte (INCY) reports better-than-expected Q4 results on strong demand for lead drug Jakafi and recently approved Opzelura.
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
by Zacks Equity Research
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex Pharmaceuticals' (VRTX) Q4 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and updates on its non-CF pipeline candidates.